title: Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases.
abstract: Intravenous immunoglobulin (IVIG) replacement therapy improves health-related quality of life in patients with a primary immunodeficiency disease, although there have been reports of adverse reactions associated with its regular administration. The study population was composed of 99 patients with primary antibody deficiencies. All the patients were diagnosed with a primary immunodeficiency disease and received at least 4 infusions of IVIG at the Children's Medical Center Hospital, Tehran, Iran over a 13-year period (1995-2007). A total of 3004 infusions were recorded, and 216 (7.2%) of these were associated with adverse reactions in 66 patients. Adverse reactions were classified as mild (172 reactions), moderate (41 reactions), and severe (3 reactions). The rate of adverse reaction varied by diagnosis from 3.35% in patients with X-linked agammaglobulinemia to 17.4% in IgG subclass deficiency. There were no age-related differences in the rates of adverse reactions. Adverse reactions to IVIG infusions are occasionally encountered; therefore, physicians and nurses should be aware of these reactions in order to manage and prevent them.
authors.affiliation: Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: S
authors.initials: S
authors.lastname: Dashti-Khavidaki
authors.forename: A
authors.initials: A
authors.lastname: Aghamohammadi
authors.forename: F
authors.initials: F
authors.lastname: Farshadi
authors.forename: M
authors.initials: M
authors.lastname: Movahedi
authors.forename: N
authors.initials: N
authors.lastname: Parvaneh
authors.forename: N
authors.initials: N
authors.lastname: Pouladi
authors.forename: K
authors.initials: K
authors.lastname: Moazzami
authors.forename: T
authors.initials: T
authors.lastname: Cheraghi
authors.forename: S A
authors.initials: SA
authors.lastname: Mahdaviani
authors.forename: S
authors.initials: S
authors.lastname: Saghafi
authors.forename: G
authors.initials: G
authors.lastname: Heydari
authors.forename: S
authors.initials: S
authors.lastname: Abdollahzade
authors.forename: N
authors.initials: N
authors.lastname: Rezaei
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001424:Bacterial Infections / Q000209:etiology / Q000276:immunology / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D003888:Desensitization, Immunologic; D004339:Drug Compounding; D064420:Drug-Related Side Effects and Adverse Reactions / Q000276:immunology* / Q000517:prevention & control; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000009:adverse effects*; D007153:Immunologic Deficiency Syndromes / Q000150:complications / Q000276:immunology / Q000628:therapy*; D007223:Infant; D007262:Infusions, Intravenous; D007492:Iran; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000209:etiology / Q000276:immunology / Q000628:therapy; D011788:Quality of Life
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016756:Immunoglobulins, Intravenous